Moleculin Biotech Balance Sheet Health
Financial Health criteria checks 4/6
Moleculin Biotech has a total shareholder equity of $26.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $38.2M and $12.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$23.55m |
| Equity | US$26.07m |
| Total liabilities | US$12.14m |
| Total assets | US$38.22m |
Recent financial health updates
We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate
Dec 20
Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?
Jul 14Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?
Feb 18Recent updates
We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate
Dec 20Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?
Jul 14Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?
Feb 18Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
Nov 01Moleculin Biotech rises 7% as WP1096 compound selected for NIAID-funded animal studies
Sep 27Moleculin brain cancer therapy WP1122 gets FDA orphan drug status
Sep 06Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
Jul 11Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial
Jul 08We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth
Mar 28We're Not Very Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate
Dec 11We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth
Aug 18Moleculin Biotech to join Russell 2000 Index
Jun 15Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Invest In Growth?
May 04Moleculin shares soar after promising Annamycin pre-clinical readout
Feb 02Moleculin Biotech under pressure on reverse stock split
Jan 29Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
Jan 15Moleculin Bio's Annamycin an Orphan Drug in U.S. for soft tissue sarcomas
Dec 29Moleculin Bio on go with mid-stage study of Annamycin for lung metastases
Dec 17Moleculin Biotech's annamycin shows encouraging action in animal study
Nov 19Moleculin Biotech EPS beats by $0.04
Nov 13Moleculin further collaborates to advance WP1122 in COVID-19
Oct 29Financial Position Analysis
Short Term Liabilities: MBRX's short term assets ($26.3M) exceed its short term liabilities ($6.8M).
Long Term Liabilities: MBRX's short term assets ($26.3M) exceed its long term liabilities ($5.3M).
Debt to Equity History and Analysis
Debt Level: MBRX is debt free.
Reducing Debt: MBRX had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MBRX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: MBRX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 16.2% each year